4.0 Article

A systematic review on the effectiveness of treatment with antidepressants in fibromyalgia syndrome

Journal

ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH
Volume 59, Issue 9, Pages 1279-1298

Publisher

WILEY-LISS
DOI: 10.1002/art.24000

Keywords

-

Categories

Funding

  1. Bundesministerium fur Bildung und Forschung
  2. Deutscher Forschungsverbund Neuropathischer Schmerz (German Research Network on Neuropathic Pain)
  3. University of Wurzburg

Ask authors/readers for more resources

Objective. To systematically review the efficacy of treatment of fibromyalgia syndrome (FMS) with antidepressants. Methods. We screened Medline, PsychINFO, SCOPUS, and the Cochrane Library databases (through October 2007) and the reference sections of original studies, meta-analyses. and evidence-based guidelines and recommendations on antidepressants in FMS. Randomized controlled trials (RCTs) on the treatment of FMS with antidepressants were analyzed. Inclusion criteria, study characteristics, quality, and all outcome measures were investigated. Results. Twenty-six of 167 studies were included. The main outcome variables reviewed were pain, fatigue, sleep, depressiveness, and quality of life. Amitriptyline, studied in 13 RCTs, was efficient in reducing pain with a moderate magnitude of benefit (pain reduction by a mean of 26%, improvement in quality of life by 30%). Selective serotonin reuptake inhibitors (SSRIs) were studied in 12 RCTs, which also showed positive results, except for 2 studies on citalopram and 1 on paroxetine. Three RCTs on the dual serotonin and noradrenaline reuptake inhibitors (SNRIs) duloxetine and milnacipran and 1 of the 2 RCTs using the monoamine oxidase inhibitor moclobemide reported a positive result. The longest study duration was 12 weeks. Conclusion. Amitriptyline 25-50 mg/day reduces pain, fatigue, and depressiveness in patients with FMS and improves sleep and quality of life. Most SSRIs and the SNRIs duloxetine and milnacipran are probably also effective. Short-term treatment of patients with FMS using amitriptyline or another of the antidepressants that were effective in RCTs can be recommended. Data on long-term efficacy are lacking.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.0
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available